<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01335347</url>
  </required_header>
  <id_info>
    <org_study_id>VXA01-001</org_study_id>
    <nct_id>NCT01335347</nct_id>
  </id_info>
  <brief_title>Safety Study of an Oral Vaccine to Prevent Avian Influenza</brief_title>
  <acronym>H5N1</acronym>
  <official_title>A Dose Escalation Phase 1 Safety and Immunogenicity Study of an Oral Viral Vector Vaccine Encoding Avian Influenza H5N1 Hemagglutinin Protein and dsRNA Adjuvant in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vaxart</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vaxart</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the safety and immunogenicity of an oral vaccine
      to prevent avian influenza. Volunteers will receive either one or two doses of research
      vaccine or placebo as part of this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency or severity of vaccine related events as measured through reported AEs</measure>
    <time_frame>up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Magnitude of humoral immune responses to avian influenza as measured by functional assays</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude of cellular immune responses to avian influenza as measured by functional assays</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Avian Influenza</condition>
  <condition>Bird Flu</condition>
  <arm_group>
    <arm_group_label>Experimental Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: One dose of a live replication incompetent adenovirus given in a capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: One or two doses of replication incompetent adenovirus given in a capsule
Other: Placebo capsules of the same size and shape</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: One dose of replication incompetent adenovirus in a capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsules of the same size and shape as the experimental</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ND1.1</intervention_name>
    <description>adenovirus with the dsRNA adjuvant, dried and put into capsules</description>
    <arm_group_label>Experimental Low Dose</arm_group_label>
    <arm_group_label>Experimental Medium Dose</arm_group_label>
    <arm_group_label>Experimental High Dose</arm_group_label>
    <other_name>Ad-HA-dsRNA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>Capsules of the same size and shape as experimental groups</description>
    <arm_group_label>Placebo Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good health as established by medical history, physical examination and laboratory
             testing at the time of enrollment.

        Exclusion Criteria:

          -  Has had any other vaccines within the past 8 weeks.

          -  Has had prior H5 avian influenza investigational vaccine.

          -  Current history of chronic alcohol consumption and/or illicit and/or recreational drug
             use.

          -  History of autoimmune related disease.

          -  History of any confirmed or suspected immunodeficient or immunosuppressive condition
             (no congenital or acquired condition that impedes normal immune response, no
             concurrent immunosuppressive therapy).

          -  Positive serology for HIV, HCV, or HBV.

          -  Previous serious reactions to vaccination such as anaphylaxis, respiratory problems,
             hives or abdominal pain.

          -  History of irritable bowel disease or other inflammatory digestive or gastrointestinal
             conditions that could affect the intended distribution or safety evaluation of an
             orally administered vaccine targeting the mucosa of the small intestine.

          -  Use of proton pump inhibitors (Nexium, Prilosec) that substantially increases stomach
             pH.

          -  Stool sample with occult blood at baseline exam
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean N Tucker, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Vaxart</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Kabongo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Accelovance</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2011</study_first_submitted>
  <study_first_submitted_qc>April 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2011</study_first_posted>
  <last_update_submitted>January 2, 2013</last_update_submitted>
  <last_update_submitted_qc>January 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>pandemic</keyword>
  <keyword>avian influenza</keyword>
  <keyword>H5N1</keyword>
  <keyword>flu</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

